内克塔治疗将于2026年4月20日召开电话会议讨论Rezpegaldesleukin治疗斑秃的Rezolve-AA二期B研究16周延长期52周顶线结果

美股速递04-20

内克塔治疗宣布，公司计划于2026年4月20日举行一场电话会议，重点讨论其药物Rezpegaldesleukin用于治疗斑秃的Rezolve-AA二期B期临床研究的最新数据。

此次会议将深入解读该研究16周延长治疗期结束后获得的52周顶线结果。这些关键数据将有助于评估该疗法在斑秃患者中的长期疗效与安全性。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1109702235?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-20 00:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109702235","market":"us","top_or_hot":-1,"title":"内克塔治疗将于2026年4月20日召开电话会议 讨论Rezpegaldesleukin治疗斑秃的Rezolve-AA二期B研究16周延长期52周顶线结果","media":"美股速递","content":"<p>内克塔治疗宣布，公司计划于2026年4月20日举行一场电话会议，重点讨论其药物Rezpegaldesleukin用于治疗斑秃的Rezolve-AA二期B期临床研究的最新数据。</p>\n<p>此次会议将深入解读该研究16周延长治疗期结束后获得的52周顶线结果。这些关键数据将有助于评估该疗法在斑秃患者中的长期疗效与安全性。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>内克塔治疗将于2026年4月20日召开电话会议 讨论Rezpegaldesleukin治疗斑秃的Rezolve-AA二期B研究16周延长期52周顶线结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n内克塔治疗将于2026年4月20日召开电话会议 讨论Rezpegaldesleukin治疗斑秃的Rezolve-AA二期B研究16周延长期52周顶线结果\n</h2>\n\n<h4 class=\"meta\">\n\n2026-04-20 00:01 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>内克塔治疗宣布，公司计划于2026年4月20日举行一场电话会议，重点讨论其药物Rezpegaldesleukin用于治疗斑秃的Rezolve-AA二期B期临床研究的最新数据。\n此次会议将深入解读该研究16周延长治疗期结束后获得的52周顶线结果。这些关键数据将有助于评估该疗法在斑秃患者中的长期疗效与安全性。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1109702235","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109702235","pubTimestamp":1776614476,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"内克塔治疗宣布，公司计划于2026年4月20日举行一场电话会议，重点讨论其药物Rezpegaldesleukin用于治疗斑秃的Rezolve-AA二期B期临床研究的最新数据。\n此次会议将深入解读该研究16周延长治疗期结束后获得的52周顶线结果。这些关键数据将有助于评估该疗法在斑秃患者中的长期疗效与安全性。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","NKTR":"内克塔治疗"},"translate_title":"Nectar Therapeutics will hold a conference call on April 20, 2026 to discuss the top-line results of the Rezolve-AA Phase II B study with Rezpegaldesleukin for alopecia areata, 16-week extension, 52-week","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1},"content_text":"内克塔治疗宣布，公司计划于2026年4月20日举行一场电话会议，重点讨论其药物Rezpegaldesleukin用于治疗斑秃的Rezolve-AA二期B期临床研究的最新数据。\n此次会议将深入解读该研究16周延长治疗期结束后获得的52周顶线结果。这些关键数据将有助于评估该疗法在斑秃患者中的长期疗效与安全性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109702235","isCrawlerRequest":true}

内克塔治疗将于2026年4月20日召开电话会议 讨论Rezpegaldesleukin治疗斑秃的Rezolve-AA二期B研究16周延长期52周顶线结果

精彩评论

内克塔治疗将于2026年4月20日召开电话会议讨论Rezpegaldesleukin治疗斑秃的Rezolve-AA二期B研究16周延长期52周顶线结果